{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:31:52Z","timestamp":1793323912046,"version":"4.5.0"},"reference-count":14,"publisher":"Open Medical Publishing","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Cancer-related bone pain remains a clinical challenge, particularly in patients with metastatic disease who have failed conventional pharmacologic therapies. Suzetrigine, a selective NaV1.8 sodium channel inhibitor, is a novel non-opioid analgesic with potential utility in nociceptive and neuropathic pain states. However, its role in advanced cancer-related pain remains unclear. We present a three-patient case series evaluating suzetrigine in patients with metastatic cancer involving the spine. All patients had extensive prior treatment histories, including opioid therapy, and demonstrated no meaningful improvement in pain following a three-week trial of suzetrigine. Treatment was discontinued due to lack of efficacy, and in one case, cost was also a contributing factor. No adverse effects were reported. These findings highlight potential limitations of suzetrigine in advanced cancer-related bone pain, particularly in opioid-tolerant patients.<\/jats:p>","DOI":"10.52965\/001c.162158","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:47:09Z","timestamp":1779468429000},"source":"Crossref","is-referenced-by-count":4,"title":["Suzetrigine for Cancer-Related Bone Pain: A Three-Patient Case Series"],"prefix":"10.52965","volume":"18","author":[{"given":"Jamal","family":"Hasoon","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03gds6c39","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas Health Science Center at Houston","department":["Department of Anesthesiology, Critical Care, and Pain Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anvinh","family":"Nguyen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pttbw34","id-type":"ROR","asserted-by":"publisher"}],"name":"Baylor College of Medicine","department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranganathan","family":"Govindaraj","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03gds6c39","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas Health Science Center at Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Robinson","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"30777","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.64719\/pb.16578","article-title":"Suzetrigine for Pain Management: An Observational Study of Early Adoption Patterns","volume":"56","author":"J. Hasoon","year":"2026","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"ref2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/ACO.0000000000001599","article-title":"Suzetrigine, a selective NaV1.8 inhibitor in acute and chronic pain: mechanistic insights, clinical outcomes, and future perspectives","volume":"39","author":"S.L. Chen","year":"2026","journal-title":"Curr Opin Anaesthesiol"},{"issue":"Suppl 1","key":"ref3","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.pain.2013.07.044","article-title":"Bone cancer pain: causes, consequences, and therapeutic opportunities","volume":"154","author":"P. Mantyh","year":"2013","journal-title":"Pain"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1097\/PR9.0000000000000867","article-title":"Reciprocal interactions between osteoclasts and nociceptive sensory neurons in bone cancer pain","volume":"6","author":"A. S. Andriessen","year":"2021","journal-title":"Pain Rep"},{"issue":"16","key":"ref5","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.2013.51.7219","article-title":"Pain and nociception: mechanisms of cancer-induced bone pain","volume":"32","author":"S. Falk","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref6","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1016\/S1470-2045(17)30612-5","article-title":"An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report","volume":"18","author":"D. E. Spratt","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9784","key":"ref7","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0140-6736(11)60236-5","article-title":"Treatment of cancer pain","volume":"377","author":"R.K. Portenoy","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"ref8","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.3390\/curroncol30070500","article-title":"Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques","volume":"30","author":"F. Mestdagh","year":"2023","journal-title":"Curr Oncol"},{"issue":"8","key":"ref9","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00520-019-04828-8","article-title":"Opioids in cancer-related pain: current situation and outlook","volume":"27","author":"B. George","year":"2019","journal-title":"Support Care Cancer"},{"issue":"4","key":"ref10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.22.02198","article-title":"Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline","volume":"41","author":"J. A. Paice","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"ref11","doi-asserted-by":"publisher","first-page":"CD012592","DOI":"10.1002\/14651858.CD012592.pub2","article-title":"Opioids for cancer pain - an overview of Cochrane reviews","volume":"7","author":"P. J. Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ref12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain","volume":"14","author":"J. D. Osteen","year":"2025","journal-title":"Pain Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.2147\/JPR.S527710","article-title":"Suzetrigine: Is This What We Have Been Waiting for or Just the Beginning?","volume":"18","author":"C. L. Robinson","year":"2025","journal-title":"J Pain Res"},{"issue":"6","key":"ref14","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/ALN.0000000000005460","article-title":"Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials","volume":"142","author":"T. Bertoch","year":"2025","journal-title":"Anesthesiology"}],"container-title":["Orthopedic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/orthopedicreviews.openmedicalpublishing.org\/article\/162158-suzetrigine-for-cancer-related-bone-pain-a-three-patient-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:45:56Z","timestamp":1793321156000},"score":1,"resource":{"primary":{"URL":"https:\/\/orthopedicreviews.openmedicalpublishing.org\/article\/162158-suzetrigine-for-cancer-related-bone-pain-a-three-patient-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":14,"URL":"https:\/\/doi.org\/10.52965\/001c.162158","relation":{},"ISSN":["2035-8164"],"issn-type":[{"value":"2035-8164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}